Yahoo
NasdaqGM - Nasdaq Real Time Price USD

Inventiva S.A. (IVA)

4.6800 -0.0250 (-0.53%)
At close: August 31 at 4:00:01 PM EDT
4.6800 0.0000 (0.00%)
After hours: August 31 at 4:44:12 PM EDT
Trade IVA on Coinbase
Chart Range Bar
Loading chart for IVA
Chart does not reflect overnight price.
  • Previous Close 4.7050
  • Open 4.6400
  • Bid 4.5500 x 100
  • Ask 4.4500 x 400
  • Day's Range 4.5250 - 4.7200
  • 52 Week Range 3.3500 - 7.9830
  • Volume 1,004,219
  • Avg. Volume 1,093,370
  • Market Cap (intraday) 1.106B
  • Beta (5Y Monthly) 0.91
  • PE Ratio (TTM) --
  • EPS (TTM) -2.2100
  • Earnings Date Sep 25, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 14.88

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.

inventivapharma.com

69

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 8/31/2026, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .

YTD Return

IVA
1.30%
CAC 40 (^FCHI)
2.27%

1-Year Return

IVA
24.39%
CAC 40 (^FCHI)
8.19%

3-Year Return

IVA
29.28%
CAC 40 (^FCHI)
13.91%

5-Year Return

IVA
62.14%
CAC 40 (^FCHI)
24.76%

Analyst Insights

View More

Analyst Price Targets

8.80
14.88 Average
4.6800 Current
26.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 7/17/2026
Analyst Cantor Fitzgerald
Rating Action Initiated
Rating Overweight
Price Action --
Price Target --

Statistics

View More

Valuation Measures

Annual
As of 8/27/2026
  • Market Cap

    1.17B

  • Enterprise Value

    969.42M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    174.89

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    185.55

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -45.08%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    6.76M

  • Net Income Avi to Common (ttm)

    -354.14M

  • Diluted EPS (ttm)

    -2.2100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    99.84M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -200.71M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

4.6800 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: